Anthropic has appointed Vas Narasimhan, CEO of Novartis, to its board of directors, a move that gives directors selected by the Long-Term Benefit Trust a majority on the company’s seven-member board. The change highlights Anthropic’s continued emphasis on governance structures designed to support its public-benefit mission.
Trust-aligned governance gains more weight
According to the announcement, the Long-Term Benefit Trust is an independent entity and holds no economic interest in Anthropic. Its role is to help ensure that the company’s governance remains aligned with its broader public-interest objectives rather than being driven solely by financial incentives. With Narasimhan joining, the trust-appointed side now holds a majority of board seats.
Regulated-industry experience joins the board
Narasimhan brings a background as a physician-scientist and is also a member of the U.S. National Academy of Medicine. During his leadership at Novartis, he oversaw the development of more than 35 new medicines. Anthropic co-founder Daniela Amodei said his experience navigating highly regulated industries would be valuable as the company deals with the governance and compliance challenges that come with advanced AI development.
Why the appointment matters
While the development is not directly tied to tokens, blockchain activity, or fundraising, it is still relevant to broader tech and digital-asset audiences watching how frontier technology firms structure control and accountability. Anthropic’s board update signals an effort to preserve long-term mission alignment as the company grows, adding another example to the ongoing debate over governance in powerful emerging technologies.